Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16Gastrointestinal 11Other hematologic neoplasm 10Lymphoid 9Thoracic 8Sarcoma 7Plasma cell 7CNS 7Gynecologic 5Genitourinary 5Dermatologic 5Classical hematology 3Myeloid 2Other neoplasm 1Other 1

Conditions

Obesity 373Neoplasms 134Breast Neoplasms 95Mucositis 94Overweight 91Sexual Dysfunction, Physiological 90Polycystic Ovary Syndrome 89Dyspnea 56Motor Activity 54Weight Loss 38Constipation 35Diabetes Mellitus 33Prostatic Neoplasms 32Head and Neck Neoplasms 30Colorectal Neoplasms 30Endometrial Neoplasms 26Lung Neoplasms 25Depression 25Diabetes Mellitus, Type 2 23Cardiovascular Diseases 23Multiple Endocrine Neoplasia Type 1 22Pain 20Anxiety Disorders 20Insulin Resistance 19Obesity, Morbid 18Pulmonary Disease, Chronic Obstructive 17Hypertension 17Sexual Dysfunctions, Psychological 16Metabolic Syndrome 16Colonic Neoplasms 16

Interventions

Melphalan 1Fibroblast Growth Factor 7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × Other × Clear all
NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡